Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Andrew De Leon
Palonosetron (Aloxi): A Second-Generation 5-Ht3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting
Baylor University Medical Center Proceedings
Medicine
Related publications
Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: Approval and Efficacy
Cancer Management and Research
Oncology
Real-World Effectiveness of Palonosetron-Based Antiemetic Regimens: Preventing Chemotherapy-Induced Nausea and Vomiting
Journal of Comparative Effectiveness Research
Health Policy
Effects of Vagotomy and 5-Ht3 Antagonist for Drug Inductivity Vomiting.
Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
5-Ht3 Receptor Antagonism by Anpirtoline, a Mixed 5-Ht1 Receptor Agonist/5-Ht3 Receptor Antagonist
British Journal of Pharmacology
Pharmacology
Evolving Role of Neurokinin 1-Receptor Antagonists for Chemotherapy-Induced Nausea and Vomiting
OncoTargets and Therapy
Oncology
Pharmacology
Efficacy of Triple Antiemetic Therapy (Palonosetron, Dexamethasone, Aprepitant) for Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Carboplatin-Based, Moderately Emetogenic Chemotherapy.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Preventing Chemotherapy-Induced Nausea and Vomiting With Netupitant/Palonosetron, the First Fixed Combination Antiemetic: Current and Future Perspective
Future Oncology
Medicine
Cancer Research
Oncology
Dronabinol for Chemotherapy-Induced Nausea and Vomiting Unresponsive to Antiemetics
Cancer Management and Research
Oncology
Palonosetron Exhibits Higher Total Control Rate Compared to First-Generation Serotonin Antagonists and Improves Appetite in Delayed-Phase Chemotherapy-Induced Nausea and Vomiting
Molecular and Clinical Oncology
Cancer Research
Oncology
